Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Madrigal Pharmaceuticals (MDGL) over the last 16 years, with Dec 2024 value amounting to $1.5 million.

  • Madrigal Pharmaceuticals' Capital Expenditures rose 10.01% to $857,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 14.81%. This contributed to the annual value of $1.5 million for FY2024, which is 1.15% down from last year.
  • As of FY2024, Madrigal Pharmaceuticals' Capital Expenditures stood at $1.5 million, which was down 1.15% from $1.5 million recorded in FY2023.
  • In the past 5 years, Madrigal Pharmaceuticals' Capital Expenditures registered a high of $1.5 million during FY2023, and its lowest value of $209,000 during FY2021.
  • Over the past 3 years, Madrigal Pharmaceuticals' median Capital Expenditures value was $1.5 million (recorded in 2024), while the average stood at $1.1 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first slumped by 62.76% in 2020, then skyrocketed by 581.57% in 2023.
  • Over the past 5 years, Madrigal Pharmaceuticals' Capital Expenditures (Yearly) stood at $334,000 in 2020, then crashed by 37.43% to $209,000 in 2021, then increased by 3.83% to $217,000 in 2022, then soared by 581.57% to $1.5 million in 2023, then fell by 1.15% to $1.5 million in 2024.